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Abstract 
Purpose. Androgen receptor (AR) and AR signaling pathways are thought to play a role in 
breast cancer (BC) and are potentially related to treatment responses and outcomes. Ankyrin 
3 (ANK3) is associated with AR stability in cancer cells. In the present study, we investigated 
the clinicopathological utility of ANK3 expression with emphasis on AR and its associated 
signalling pathway at transcriptomic and proteomic phases. 
Patients and Methods. The Molecular Taxonomy of Breast Cancer International Consortium 
(METABRIC) cohort (n = 1,980) and The Cancer Genome Atlas (TCGA) dataset (n = 1,039) 
were used to assess the expression and significance of ANK3 mRNA and other AR signalling 
pathway-associated gene signature. Using immunohistochemistry, ANK3 protein expression 
was evaluated in large (n = 982) cohort of early-stage BC with long-term follow-up and 
compared with clinicopathological characteristics and its prognostic value in the whole 
cohort and the subgroups stratified by AR protein expression.  
Results. An AR-related gene signature was developed, comprising 20 genes, which included 
ANK3. This AR-related gene signature was significantly associated with AR mRNA 
expression, oestrogen receptor, human epidermal growth factor receptor 2 (HER2) status and 
the patients’ outcomes. In tumours with high AR protein expression (n = 614), high ANK3 
protein expression was significantly associated with progesterone receptor positivity and it 
was independently associated with the good outcomes (p = 0.025).  
Conclusions. This study indicates that ANK3 is related AR signalling pathway and is 
associated with BC prognosis.  
Keywords: invasive breast cancer, androgen receptor, ankyrin 3, prognostic marker. 
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BACKGROUND 
Treatments of breast cancer (BC) are generally determined on the basis of the molecular 
phenotype of the primary tumour [1, 2]. However, the biological heterogeneity of BC 
constitutes an important determinant of treatment sensitivity, success and outcomes. 
Hormone-dependent pathways, including androgen receptor (AR) signalling pathways, are 
thought to play an important role in BC cell proliferation [3, 4]. Previous studies have 
indicated that AR and AR signaling pathways are associated with treatment resistance and 
prognosis of BC [5, 6]. In previous research, we found that approximately 55% of BC had 
high AR expression, which was observed in 42% of human epidermal growth factor receptor 
2 (HER2)-positive tumours and in 20% of triple negative BC (TNBC) [7]. Some studies 
indicate that high AR expression is a good prognostic factor in BC [7, 8]. However, in HER2-
positive and TNBC subtypes, AR signalling pathways are considered to play an important 
role in tumour progression. He et al. suggested that AR promotes the growth of HER2-
positive BC via crosstalk with the intracellular HER2 downstream pathway [9]. The luminal-
AR BC subtype, a molecular subtype of TNBC, not only expresses AR but also has enriched 
hormone-dependent pathways, as demonstrated at the global transcriptomic level [10, 11]. It 
has also been shown in oestrogen receptor (ER)-positive and HER2-negative BC that 
aberrant AR-related oncogenic pathway activation is associated with resistance to endocrine 
therapy [12].   
Ankyrin 3 (ANK3), a member of the ankyrin family of membrane-associated proteins, is 
believed to link integral membrane proteins to cytoskeletal components. Ankyrins are 
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associated with cytoplasmic structures and are also necessary in the regulation of cell 
migration and adhesion and for the maintenance of cellular membrane domains [13-15]. 
ANK3 has been suggested to play a role in regulating the stability and turnover of AR and is 
closely associated with AR genomic activities [16]. AR signaling pathway promotes cancer 
cell proliferation by increasing cyclin-dependent kinase activity [17, 18] and ANK3 regulates 
the expression of cell cycle components as cyclins A and B [16]. Hence, ANK3 may play an 
important role in AR signaling pathway in cancer. However, the association between ANK3 
expression and AR signaling pathway in BC remains poorly defined.  In this study, ANK3 
was first evaluated as a component of the AR signaling pathway in BC, utilising well 
characterised large cohort transcriptomic databases. The clinicopathological and prognostic 
significance of ANK3 protein expression levels was assessed using immunohistochemistry 
(IHC) in a large series of BC patients’ specimens. 
MATERIALS AND METHODS 
Cluster Analysis of AR-Signaling-Pathway-Associated Genes 
Gene Ontology (GO) Consortium is the large genomic annotation project and widely used as 
biological databases for annotating genes to the previous evidence regarding their biological 
role [19, 20]. GO terms are divided into 3 categories as biological process, molecular 
function and cellular component [21]. In GO terms of the biological process, gene symbols 
related to ‘Regulation Of Androgen Receptor Signaling Pathway (GO: 0060765)’ were 
accessed using the online database Gene Set Enrichment Analysis (http://
s o f t w a r e . b r o a d i n s t i t u t e . o r g / g s e a / m s i g d b / c a r d s /
GO_REGULATION_OF_ANDROGEN_RECEPTOR_SIGNALING_PATHWAY) [22, 23]. 
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The mRNA expression data of these genes, including ANK3, together with the 
clinicopathological characteristics and outcomes of patients with BC, were collected from the 
Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) dataset [24, 
25] (n = 1,980) and the Cancer Genome Atlas (TCGA) [26] dataset (n  = 1,039) provided by 
cBioPortal [27]. 
The normalisation method of mRNA expression in the METABRIC cohort was previously 
described [24]. TCGA mRNA data was log2-transformed prior to cluster analysis. For cluster 
analysis [28] and heat mapping construction, Cluster 3.0 and Java Treeview was used [29]. 
Data were filtered to remove all genes that did not have at least one observation with absolute 
values greater than 2.0 or whose maximum minus minimum values were less than 2.0.  
ANK3 Protein Expression 
A total of 982 BC patients who underwent surgery at Nottingham City Hospital in the UK 
between 1987 and 1998 (referred to as the Nottingham Primary Breast Cancer Series) were 
included in this study. All patients had undergone breast-conserving surgery or modified 
radical mastectomy without any neoadjuvant treatment. The availability and assessment of 
hormone receptors (AR, ER and progesterone receptor [PR]), HER2 and Ki67 were described 
in previous studies [7, 30-37]. The cohort was stratified on the basis of AR expression [7], 
with 614 patients (62.5%) with high and 368 patients (37.5%) with low AR expression 
(Supplementary Table 1). 
ANK3 protein expression was assessed by IHC using an anti-ANK3 antibody (HPA055643; 
Merck, Darmstadt, Germany) diluted 1:300 as previously described [38–40]. In order to 
evaluate the pattern of ANK3 protein expression, 15 full-face BC tissue sections were 
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assessed prior to staining the whole cohort (n = 982) prepared as tissue microarrays (TMAs). 
Immunostained TMA sections were digitally scanned using a NanoZoomer (Hamamatsu 
Photonics, Tokyo, Japan). Cytoplasmic staining of ANK3 in cancer cells was assessed using 
the H-score method on the basis of intensity scoring (0 = negative, 1 = weak, 2 = moderate, 3 
= strong) and proportion scoring (0–100) as previously reported [41, 42]. 
Statistical Analysis 
Statistical analyses were conducted using SPSS v24.0 (IBM, Armonk, NY, USA). The 
relationship between ANK3 mRNA with ANK3 protein expression and AR mRNA expression 
was examined using Pearson’s correlation coefficient test. In order to assess the associations 
between AR mRNA expression and groups stratified by the AR-related gene signature, the 
Mann–Whitney U test was used. The chi-square test as univariate analysis and the logistic 
regression test as multivariate analysis were used to assess several clinicopathological 
factors, including tumour size, lymph node status, histological grade, ER, PR, HER2 and 
molecular subtypes, stratified by groups based on AR-related gene signature and levels of 
ANK3 protein expression. In order to assess the prognostic utility of ANK3 expression, 
Kaplan–Meier survival curves was used. In univariate and multivariate analyses, to assess the 
associations between clinicopathological factors, including ANK3 expression, and prognosis, 
95% confidence intervals (CIs) were assessed using the Cox proportional hazards regression 
model. In these survival analyses, the median value (H-score = 120) was used as a cut-off 
point to divide the samples into high and low expression groups. 
RESULTS 
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ANK3 mRNA Expression and AR Signaling Pathway Gene Signature 
High ANK3 mRNA expression was significantly associated with high AR mRNA expression 
(METABRIC: r = 0.019, p = 0.39; TCGA: r = 0.28, p < 0.0001) in TCGA cohort. An AR-
related gene signature was developed using genomic data filtering, and this comprised 20 
genes, including ANK3 and 19 other relevant genes available in the databases: ARRB2, 
BUD31, DAB2, DDX5, EP300, FOXP1, HDAC1, HDAC6, HEYL, PARK7, PHB, PIAS2, 
PRMT2, RNF14, RNF6, SFRP1, SIRT1, SMARCA4 and TRIM68 (Supplementary Table 2). 
Using the dendrogram of cluster analysis, the METABRIC and TCGA cohorts were stratified 
into two groups on the basis of the AR-signaling-pathway-associated genes [Figs. 1(a) and 
1(b)], where tumours in group 1 had significantly lower AR mRNA expression than that in 
Group 2 (p < 0.0001). Group 1 tumours included 899 (45%) from the METABRIC and 541 
(52%) from TCGA cohort.  
In the METABRIC and TCGA cohorts, multivariate analysis indicated that the AR-related 
gene signature in group 2 was significantly associated with lower grade (p = 0.0070, and p = 
0.0093 respectively), ER positivity (p < 0.0001, and p < 0.0001 respectively), and HER2 
positivity (p < 0.0001 and p < 0.0001; Table 1). In the METABRIC cohort, the AR-related 
gene signature was significantly associated with molecular subtype (p < 0.0001), with 83% of 
the basal-like tumours in group 1 and 90% of the luminal B tumours in group 2 (Table 1). 
Although the expression of ANK3 and AR mRNA was not a significant independent 
prognostic factor in BC (Supplementary Figure 1), there was an association between AR-
related gene signature subgroups and patients’ outcomes, where patients with the AR-related 
gene signature group 2 showed significantly worse outcome than those with Group 1 tumours 
[METABRIC: hazard ratio (HR) 1.25, 95% CI: 1.09-1.43, p = 0.0013; TCGA: HR 1.61, 95% 
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CI: 1.11-2.32, p = 0.011; Figs. 1(c) and 1(d)]. On multivariate analysis, AR-related gene 
signature group 2 was an independent prognostic factor predicting poor outcomes in both 
cohorts (METABRIC: HR 1.23, 95% CI: 1.06-1.42, p = 0.0066; TCGA: HR 1.82, 95% CI: 
1.08-3.06, p = 0.026; Table 2).  
Immunohistochemical Expression of ANK3 Protein 
The assessment of ANK3 in full-face tissue sections indicated that the pattern of ANK3 
expression in cancer cells was homogeneous, but it differed from that in normal mammary 
glands [Figs. 2(a)–2(c)]. ANK3 expression was observed in the normal glandular and luminal 
epithelial cells, where it was stronger than the surrounding myoepithelial cells. ANK3 
immunopositivity was observed in the cytoplasm of invasive cancer cells and was typically 
weaker than in the adjacent normal epithelial cells [Figs. 2(c)–2(e)]. 
In 198 cases in the METABRIC dataset, which overlapped with the Nottingham Primary 
Series, ANK3 mRNA and ANK3 protein expression were significantly correlated (r = 0.15, p 
= 0.039). In the Nottingham series, 579 (59%) tumours had low ANK3 expression (H-score < 
120) and 403 (41%) had high ANK3 expression (H-score > 120). High AR expression was 
present in 614 (63%) tumours and low AR expression was present in 368 (37%). Among 
those with high AR expression, 250 (41%) also had high ANK3 expression. A similar 
proportion (153, 42%) had high ANK3 expression in the low AR expression group (n = 368). 
AR expression was not associated with ANK3 expression on proteomic analysis (p = 0.79). 
When all 982 cases were combined (i.e. not stratified according to AR expression), ANK3 
was not a significant prognostic factor (Supplementary Figure 2). 
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In tumours with high AR expression, high ANK3 expression was significantly associated 
with PR positivity (p = 0.014; Supplementary Table 3). In terms of BC-specific survival, high 
AR protein expression was a significant good prognostic factor (HR 0.66, 95% CI: 0.52-0.84, 
p = 0.00066; Supplementary Figure 3). Low ANK3 protein expression was a poor prognostic 
factor in patients with high AR expression [HR 1.49, 95% CI: 1.07-2.09, p  = 0.020; Figs. 
3(a)–3(e)], but not in those whose tumours had low AR expression (HR 0.89, 95% CI: 
0.62-1.28, p = 0.53; Supplementary Figure 4). In high-AR-expressing BC patients, univariate 
analysis using the Cox proportional hazards regression analysis identified low ANK3 
expression, large tumour size (HR 2.61, p < 0.0001), positive nodal status (HR 2.84, p < 
0.0001) and high histological grade (HR 3.27, p < 0.0001) as poor prognostic factors. On 
multivariate analysis, low ANK3 protein expression was an independent prognostic factor 
predicting poor outcomes in BC with high AR expression (HR 1.47, p = 0.025; Table 3). 
DISCUSSION 
AR expression is a crucial factor in the progression of BC, as it controls the expression of 
various genes and proteins through a genomic pathway [5, 6]. In this pathway, AR mediates 
intracellular steroid hormone-related signaling pathways to regulate the transcription of target 
genes in conjunction with other transcription factors, such as signal transducers and activators 
of transcription [43, 44]. As a mechanism involved in the development of BC, AR expression 
might be involved in the crosstalk with epidermal growth factor receptor pathways, such as 
human epidermal growth factor receptor 1 (EGFR) and HER2 signaling [45]. In this study, 
there were a significant correlation between ANK3 and AR mRNA and ANK3 was one of the 
gene component of the AR-related gene signature. When BC was classified into 2 groups 
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based on the expression of AR-related gene signature, the group 2 gene signature, which was 
associated with high AR mRNA expression and present in 90% of luminal B tumours, was a 
significant prognostic factor indicating poor outcomes in BC. This finding suggests that 
aberrant AR-related oncogenic pathway activation is associated with a number of factors that 
portend a poor BC outcome. 
In a previous study using microarray gene expression analysis, the downregulation of ANK3 
was included in an 11-gene signature associated with poor prognosis in patients with various 
cancers including BC [46]. In a meta-analysis of gene expression signatures in BC, the 
downregulation of ANK3 appeared to enhance cancer cell differentiation, proliferation and 
metastasis [47]. Previous research using microarray data of prostate cancer suggested that 
low ANK3 expression is related to positivity for ERG, member of the erythroblast 
transformation-specific family [48]. ERG is correlated with AR activity [49], transcriptional 
stability [50] and stem cell maintenance [51] in multiple cancers. Prostate cancer cells with 
ANK3 knockdown exhibit significant increases in cell invasion through an AR-dependent 
mechanism as a regulator of AR protein stability [16]. In the present study, the association 
between ANK3 protein expression and outcomes was highly significant in BC with high AR 
expression. In addition, high ANK3 protein expression was associated with PR positivity. 
These findings suggest that ANK3 may play an important role in the maintenance of 
hormonal activity, and AR stabilisation by ANK3 may therefore be related to the improved 
outcomes in BC patients with high AR expression. A proportion of ER-negative BC are 
generally considered to retain active AR signaling [6, 52]. Several prospective clinical trials 
of AR-targeted therapies have been conducted on TNBC with high AR expression. These 
trials indicated that treatment with an AR inhibitor is feasible, with a clinical benefit rate of 
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approximately 20% in TNBC [53-55]. The upregulation of ANK3 may increase AR stability 
and improve the response to an AR inhibitor in TNBC. Further functional and translational 
research is necessary in order to explore the association of ANK3 with AR stability with the 
efficacy of treating BC with an AR inhibitor. 
In conclusion, the AR signaling pathway and ANK3 mRNA expression are associated with 
AR mRNA expression and BC prognosis. High ANK3 protein expression is an independent 
prognostic factor in BC with high AR expression. Overall, these findings indicate that ANK3 
may play an important role in breast tumour progression and, in conjunction with AR, may be 
related to BC outcomes. 
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Figures Captions 
Fig. 1. Prognostic utility of an androgen receptor (AR)-related gene signature, including 
ANK3 mRNA expression.  
Heat map of the AR-related gene signature for the (a) METABRIC and (b) TCGA cohorts 
generated by unsupervised cluster analysis, showing a clear division of cases between Group 
1 and Group 2 on the basis of the AR-related gene expression. The overall survival of patients 
!20
with breast cancer with the AR-related Group 2 gene signature was significantly worse than 
that of those with the Group 1 gene signature in the (c) METABRIC and (d) TCGA cohorts. 
Fig. 2. Morphological characteristics of ANK3 immunohistochemistry in breast cancer tissue.  
(a) ANK3 immunoreactivity differs between invasive cancer cells and adjacent normal 
mammary glandular tissues (black arrow: invasive cancer cells; white arrow: normal 
mammary gland). Immunoreactivity in normal mammary gland cells is stronger than that in 
invasive cancer cells (magnification: x100). (b) Invasive cancer cells showing uniform ANK3 
immunoreactivity primarily in the cytoplasm (magnification: x200). (c) ANK3 
immunoreactivity is uniformly strong in normal epithelial cells and weaker in myoepithelial 
cells than in glandular cells (magnification: x400). Tissue microarray images of breast cancer 
tissue samples immunohistochemically stained for ANK3, showing (d) no staining, (e) weak 
staining and (f) strong staining in the cytoplasm of cancer cells (magnification: x200). 
Fig. 3. ANK3 protein expression in breast cancer and cumulative survival rates stratified by 
ANK3 expression. (a–d) ANK3 and AR expression in breast cancer. Case 1: high ANK3 (a) 
and high AR (b) expression. Case 2: low ANK3 (c) and high AR (d) expression 
(magnification: x200 for all images). (e) With high AR expression, BC-specific survival was 
significantly worse in those with low than high ANK3 expression. 
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Table 1. Clinicopathological characteristics of breast cancer associated with AR signaling pathway-related gene signature.  
METABRIC cohort TCGA cohort
Factors
Genes signature associated with         
the AR pathway p-value Factors
Genes signature associated with     
the AR pathway p-value
Group 1 Group 2 Univariate Multivariate Group 1 Group 2 Univariate Multivariate
Tumour 
size
> 2cm 564 (42.2%) 774 (57.8%)
< 0.0001* 0.00065* Tumour size
T2-4 388 (50.5%) 381 (49.5%)
0.079 0.098
< 2cm 319 (51.8%) 297 (48.2%) T1 153 (56.7%) 117 (43.3%)
Nodal 
status
Positive 413 (44.0%) 525 (56.0%)
0.28 0.66 Nodal status
Positive 261 (49.8%) 263 (50.2%)
0.11 0.70
Negative 481 (46.5%) 554 (53.5%) Negative 278 (54.8%) 229 (45.2%)
Grade
Grade 3 444 (46.6%) 508 (53.4%)
0.22 0.0070* Grade
Grade 3 233 (56.7%) 178 (43.3%)
0.020 0.0093*
Grade 1, 2 412 (43.8%) 528 (56.2%) Grade 1, 2 272 (49.1%) 282 (50.9%)
ER
Positive 569 (37.8%) 937 (62.2%)
< 0.0001* < 0.0001* ER
Positive 340 (44.5%) 424 (55.5%)
< 0.0001* < 0.0001*
Negative 330 (69.6%) 144 (30.4%) Negative 183 (79.9%) 46 (20.1%)
PR
Positive 409 (39.3%) 631 (60.7%)
< 0.0001* 0.90 PR
Positive 303 (45.8%) 358 (54.2%)
< 0.0001* 0.80
Negative 490 (52.1%) 450 (47.9%) Negative 215 (65.7%) 112 (34.3%)
HER2
Positive 104 (42.1%) 143 (57.9%)
0.27 < 0.0001* HER2
Positive 57 (32.6%) 118 (67.4%)
< 0.0001* < 0.0001*
Negative 795 (45.9%) 938 (54.1%) Negative 385 (56.6%) 295 (43.4%)
Subtypes
Luminal A 328 (45.7%) 390 (54.3%)
< 0.0001* -
 
Luminal B 47 (9.6%) 441 (90.4%)
HER2-enriched 60 (25.0%) 180 (75.0%)
Basal-like 274 (83.3%) 55 (16.7%)
Normal-like 186 (93.5%) 13 (6.5%)
Abbreviations: ER: oestrogen receptor; PR: progesterone receptor; HER2: human epidermal growth factor receptor 2; AR: androgen receptor. 
* Significant difference, p < 0.05.
Table 2. Survival analysis based on clinicopathological characteristics of breast cancer, including AR signaling pathway-related gene signature. 
Factors
METABRIC cohort
Factors
TCGA cohort
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis 
Hazard 
Ratio 95% CI p-value
Hazard 
Ratio 95% CI p-value
Hazard 
Ratio 95% CI p-value
Hazard 
Ratio 95% CI p-value
AR related  
signature
Group 1 Reference Reference
AR related  
signature
Group 1 Reference Reference
Group 2 1.25 1.09-1.43 0.0013* 1.23
1.06-1.4
2 0.0066* Group 2 1.61
1.11-2.3
2 0.011* 1.82
1.08-3.0
6 0.026*
Tumour 
size
< 2cm Reference Reference
Tumour 
size
T2-4 Reference Reference
> 2cm 1.83 1.57-2.15 < 0.0001* 1.60
1.36-1.8
9 < 0.0001* T1 1.67
1.07-2.6
2 0.026* 1.18
0.66-2.0
9 0.58
Nodal 
status
Negative Reference Reference
Nodal 
status
Negative Reference Reference
Positive 1.86 1.63-2.12 < 0.0001* 1.62
1.40-1.8
6 < 0.0001* Positive 2.05
1.38-3.0
2 0.00033* 1.75
1.05-2.9
1 0.032*
Grade
Grade1-2 Reference Reference
Grade
Grade1-2 Reference Reference
Grade 3 1.42 1.24-1.63 < 0.0001* 1.10
0.94-1.2
8 0.25 Grade 3 1.36
0.92-2.0
0 0.13 0.93
0.54-1.6
0 0.78
ER
Positive Reference Reference
ER
Positive Reference Reference
Negative 1.37 1.18-1.59 < 0.0001* 1.08
0.88-1.3
2 0.46 Negative 1.69
1.13-2.5
2 0.011* 1.61
0.73-3.5
6 0.24
PR
Positive Reference Reference
PR
Positive Reference Reference
Negative 1.44 1.26-1.64 < 0.0001* 1.29
1.09-1.5
2 0.0025* Negative 1.55
1.06-2.2
7 0.025* 1.18
0.57-2.4
7 0.66
HER2
Negative Reference Reference
HER2
Negative Reference Reference
Positive 1.57 1.31-1.89 < 0.0001* 1.27
1.04-1.5
6 0.022* Positive 1.57
0.95-2.5
9 0.076 1.24
0.70-2.2
0 0.46
Abbreviations: ER: oestrogen receptor; PR: progesterone receptor; CI: confidence interval; HER2: human epidermal growth factor receptor 2; AR: androgen receptor. 
* Significant difference, p < 0.05.
Table 3. Survival analysis based on clinicopathological characteristics of breast cancer, including ANK3 expression in tumours with high AR 
expression group. 
  
Factors
Univariate analysis Multivariate analysis 
Hazard Ratio 95% CI p-value Hazard Ratio 95% CI p-value
ANK3 expression
High Reference Reference
Low 1.49 1.07–2.09 0.020* 1.47 1.05–2.07 0.025*
Tumour size
<2 cm Reference Reference
>2 cm 2.61 1.86–3.69 <0.0001* 1.75 1.22–2.51 0.0024*
Nodal status
Negative Reference Reference
Positive 2.84 2.05–3.92 <0.0001* 2.22 1.58–3.11 <0.0001*
Histological grade
Grades 1 and 2 Reference Reference
Grade 3 3.27 2.36–4.53 <0.0001* 2.23 1.57–3.16 <0.0001*
Subtypes
HR-positive/HER2-negative Reference Reference
HER2-positive 3.49 2.40–5.08 <0.0001* 2.31 1.55–3.44 <0.0001*
Triple negative 1.6 0.83–3.05 0.16 1.27 0.65–2.47 0.49
Abbreviations: ANK3: ankyrin 3; AR: androgen receptor; CI: confidence interval; HER2: human epidermal growth factor receptor 2; HR: hormone receptor. 
*Significant difference, p < 0.05.

Figure 2 
a)
b)
c)
d)
e)
f)

Supplementary Table 1. Patients’ characteristics of high and low androgen receptor expression groups in the Nottingham primary 
cohort 
Factors
Expression of AR
p-value
High group Low group
Age range in year 24-70 (median: 54) 25-70 (median: 51.5) <0.0001*
ANK3
High 250 (62.0%) 153 (38.0%)
0.79
Low 364 (62.9%) 215 (37.1%)
Menopausal status
Pre- 236 (58.0%) 171 (42.0%)
0.013*
Post- 378 (65.7%) 197 (34.3%)
Tumour size
>2cm 313 (58.8%) 219 (41.2%)
0.0094*
<2cm 301 (66.9%) 149 (33.1%)
Nodal status
Positive 239 (62.6%) 143 (37.4%)
0.98
Negative 375 (62.5%) 225 (37.5%)
Histological grade
Grade 3 232 (46.1%) 271 (53.9%)
<0.0001*
Grade 1 and 2 382 (79.7%) 97 (20.3%)
Subtypes
HR-positive/HER2-negative 510 (76.7%) 155 (23.3%)
<0.0001*HER2-positive 72 (56.7%) 55 (43.3%)
Triple negative 32 (16.8%) 158 (83.2%)
Type of breast surgery
Breast-conserving surgery 282 (65.6%) 148 (34.4%)
0.081
Mastectomy 332 (60.1%) 220 (39.9%)
Axillary surgery
Sampling alone 371 (62.2%) 225 (37.8%)
0.92Axillary lymph node dissection 239 (62.6%) 143 (37.4%)
No surgery 4 (100.0%) 0 (0.0%)
Chemotherapy
Yes 83 (39.9%) 125 (60.1%)
<0.0001*No 512 (69.8%) 222 (30.2%)
Unknown 19 (47.5%) 21 (52.5%)
Endocrine therapy
Yes 258 (69.2%) 115 (30.8%)
0.0020*No 337 (59.2%) 232 (40.8%)
Unknown 19 (47.5%) 21 (52.5%)
Abbreviations: ANK3: ankyrin 3; HER2: human epidermal growth factor receptor 2; HR: hormone receptor.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
* Significant difference p < 0.05.
Supplementary Table 2. List of genes in the gene signature associated with AR signaling pathway 
Gene symbol Gene name
ANK3 Ankyrin 3
ARRB2 Arrestin Beta 2
BUD31 BUD31 Homolog
DAB2 DAB2, Clathrin Adaptor Protein
DDX5 DEAD-Box Helicase 5
EP300 E1A Binding Protein P300
FOXP1 Forkhead Box P1
HDAC1 Histone Deacetylase 1
HDAC6 Histone Deacetylase 6
HEYL Hes Related Family BHLH Transcription Factor With YRPW Motif-Like
PARK7 Parkinsonism Associated Deglycase
PHB Prohibitin
PIAS2 Protein Inhibitor Of Activated STAT 2
PRMT2 Protein Arginine Methyltransferase 2
RNF14 Ring Finger Protein 14
RNF6 Ring Finger Protein 6
SFRP1 Secreted Frizzled Related Protein 1
SIRT1 Sirtuin 1
SMARCA4 SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily A, Member 4
TRIM68 Tripartite Motif Containing 68
Supplementary Table 3. Correlation between ANK3 expression and clinicopathological characteristics of breast cancer stratified by AR expression.  
Factors
High AR group Low AR group
Expression of ANK3
p-value
Expression of ANK3
p-value
High Low High Low
Tumour size
>2 cm 120 (38.3%) 193 (61.7%)
0.22
95 (43.4%) 124 (56.6%)
0.40
<2 cm 130 (43.2%) 171 (56.8%) 58 (38.9%) 91 (61.1%)
Nodal status
Positive 95 (39.7%) 144 (60.3%)
0.70
62 (43.4%) 81 (56.6%)
0.58
Negative 155 (41.3%) 220 (58.7%) 91 (40.4%) 134 (59.6%)
Histological grade
Grade 3 96 (41.4%) 136 (58.6%)
0.80
119 (43.9%) 152 (56.1%)
0.13
Grades 1 and 2 154 (40.3%) 228 (59.7%) 34 (35.1%) 63 (64.9%)
ER
Positive 225 (40.8%) 326 (59.2%)
0.86
64 (36.4%) 112 (63.6%)
0.052
Negative 25 (39.7%) 38 (60.3%) 89 (46.4%) 103 (53.6%)
PR
Positive 195 (43.7%) 251 (56.3%)
0.014*
51 (38.9%) 80 (61.1%)
0.44
Negative 55 (32.7%) 113 (67.3%) 102 (43.0%) 135 (57.0%)
HER2
Positive 29 (40.3%) 43 (59.7%)
0.94
25 (45.5%) 30 (54.5%)
0.53
Negative 221 (40.8%) 321 (59.2%) 128 (40.9%) 185 (59.1%)
Subtypes
HR-positive/HER2-negative 208 (40.8%) 302 (59.2%)
1.00
56 (36.1%) 99 (63.9%)
0.20HER2-positive 29 (40.3%) 43 (59.7%) 25 (45.5%) 30 (54.5%)
Triple negative 13 (40.6%) 19 (59.4%) 72 (45.6%) 86 (54.4%)
Ki67
High (>10%) 120 (44.4%) 150 (55.6%)
0.12
100 (44.1%) 127 (55.9%)
0.59
Low (<10%) 85 (37.6%) 141 (62.4%) 27 (40.3%) 40 (59.7%)
Abbreviations: ANK3: ankyrin 3; AR: androgen receptor; ER: oestrogen receptor; PR: progesterone receptor; HR: hormone receptor. 
Some variables have missing data. 
*Significant difference, p < 0.05.




